Abstract:One of the main obstacles to the successful treatment of cancer is the phenomenon of drug resistance. A common strategy to overcome resistance is the use of combination therapies. However, the space of possibilities is huge and efficient search strategies are required. Machine Learning (ML) can be a useful tool for the discovery of novel, clinically relevant anti-cancer drug combinations. In particular, deep learning (DL) has become a popular choice for modeling drug combination effects. Here, we set out to examine the impact of different methodological choices on the performance of multimodal DL-based drug synergy prediction methods, including the use of different input data types, preprocessing steps and model architectures. Focusing on the NCI ALMANAC dataset, we found that feature selection based on prior biological knowledge has a positive impact—limiting gene expression data to cancer or drug response-specific genes improved performance. Drug features appeared to be more predictive of drug response, with a 41% increase in coefficient of determination (R 2 ) and 26% increase in Spearman correlation relative to a baseline model that used only cell line and drug identifiers. Molecular fingerprint-based drug representations performed slightly better than learned representations—ECFP4 fingerprints increased R 2 by 5.3% and Spearman correlation by 2.8% w.r.t the best learned representations. In general, fully connected feature-encoding subnetworks outperformed other architectures. DL outperformed other ML methods by more than 35% (R 2 ) and 14% (Spearman). Additionally, an ensemble combining the top DL and ML models improved performance by about 6.5% (R 2 ) and 4% (Spearman). Using a state-of-the-art interpretability method, we showed that DL models can learn to associate drug and cell line features with drug response in a biologically meaningful way. The strategies explored in this study will help to improve the development of computational methods for the rational design of effective drug combinations for cancer therapy. Cancer therapies often fail because tumor cells become resistant to treatment. One way to overcome resistance is by treating patients with a combination of two or more drugs. Some combinations may be more effective than when considering individual drug effects, a phenomenon called drug synergy. Computational drug synergy prediction methods can help to identify new, clinically relevant drug combinations. In this study, we developed several deep learning models for drug synergy prediction. We examined the effect of using different types of deep learning architectures, and different ways of representing drugs and cancer cell lines. We explored the use of biological prior knowledge to select relevant cell line features, and also tested data-driven feature reduction methods. We tested both precomputed drug features and deep learning methods that can directly learn features from raw representations of molecules. We also evaluated whether including genomic features, in addition to gene expression data, improves the predictive performance of the models. Through these experiments, we were able to identify strategies that will help guide the development of new deep learning models for drug synergy prediction in the future.

[Newly discovered role of glomerulonephritis mediators].

Pan-Cancer Drug Sensitivity Prediction from Gene Expression using Deep Learning

A Comprehensive Investigation of Active Learning Strategies for Conducting Anti-Cancer Drug Screening

A systematic evaluation of deep learning methods for the prediction of drug synergy in cancer

Understanding the Sources of Performance in Deep Drug Response Models Reveals Insights and Improvements

[Study on the method of using ICP-MS to determine Se in the edible fungi].

Learning and actioning general principles of cancer cell drug sensitivity

A comprehensive benchmarking of machine learning algorithms and dimensionality reduction methods for drug sensitivity prediction

Learning Curves for Drug Response Prediction in Cancer Cell Lines

Precision Anti-Cancer Drug Selection via Neural Ranking

Deep learning methods for drug response prediction in cancer: Predominant and emerging trends

Pathway-Guided Deep Neural Network toward Interpretable and Predictive Modeling of Drug Sensitivity

Anti-cancer Drug Synergy Prediction in Understudied Tissues using Transfer Learning

Enhancing drug and cell line representations via contrastive learning for improved anti-cancer drug prioritization

Influencing factors on false positive rates when classifying tumor cell line response to drug treatment

NeuMF: Predicting Anti-cancer Drug Response Through a Neural Matrix Factorization Model

Temporal-spatial gait parameters and neurodevelopment in very-low-birth-weight preterm toddlers at 18-22 months.

Abstract 3537: Assessing machine learning models of drug response predictions using orthotopic patient-derived xenograft

Cancer drug sensitivity prediction from routine histology images

Improving drug response prediction via integrating gene relationships with deep learning

SYSTEMATIC ASSESSMENT OF ANALYTICAL METHODS FOR DRUG SENSITIVITY PREDICTION FROM CANCER CELL LINE DATA